Transgenic (TG) rats bearing a probasin promoter/simian virus 40 T antigen (SV40 Tag) construct were treated with antiandrogens to examine their ability to suppress prostate carcinogenesis. Finasteride and flutamide were administered to 10-week-old TG rats five times a week for 2, 5 and 7 weeks. Antiandrogen-treated prostates exhibited atrophic glandular structures with almost no expression of SV40 Tag and only weak signals for androgen receptors. Furthermore, quantitative data for ventral prostate adenocarcinomas showed significant decrease with antiandrogen treatment. Both finasteride and flutamide had the ability to suppress SV40 Tag-driven carcinogenesis through their different antiandrogenic mechanisms, suggesting that this TG model is suitable for exploring the potential of agents to inhibit prostate cancer development.
Introduction
Among US men, prostate cancer is the most common non-cutaneous neoplasm and the second leading cause of cancer death. It has been estimated that there will be approximately 234 460 new cases of prostate cancer and 27 350 associated deaths in the United States in 2006. 1 Over 60% of these newly diagnosed cases of prostate cancer will be pathologically advanced; at this stage, there is no cure and the prognosis is dismal. Since the frequency of latent prostatic tumors has been shown to increase with each decade of life from the 50s (5.3-14%) to the 90s (40-80%) 2 and relatively long time periods are necessary for progression to actual prostate cancer, the concept of chemoprevention has attracted much attention.
The majority of prostate cancers initially respond to androgen ablation therapy because of hormone-dependent growth, 3 but relapse with generation of hormoneindependent cancer cell occurs and eventually leads to a fatal outcome in many cases. 4, 5 Although androgen ablation at this hormone refractory stage is ineffective, androgen deprivation strategy as an early intervention may delay the promotion and/or progression of prostate cancer, resulting in reduced morbidity and mortality.
Approaches to influence androgen levels in prostatic tissue include (a) inhibition of the pituitary secretion of luteinizing hormone (LH) by LH-releasing hormone (LHRH) analogs, (b) prevention of the conversion of testosterone to dihydrotestosterone (DHT) by 5a-reductase in the prostate and (c) blocking prostatic androgen receptors (ARs) using steroid-like antagonists with no intrinsic activity, to reduce potentially unacceptable systemic toxicity. 6 One such agonist is the azasteroid finasteride. 7 Another potential suppressive agent is the nonsteroidal antiandrogen flutamide, which exerts effects by interfering with the binding of DHT or testosterone to the AR. 5 The study of prostate cancer chemoprevention and treatment has been hindered by the lack of appropriate animal models. Recently, we have established transgenic (TG) rats, designated TRAP (Transgenic Rat for Adenocarcinoma of the Prostate), bearing a probasin promoter/ simian virus 40 T antigen (SV40 Tag) construct in which androgen-dependent prostate cancers develop rapidly. [8] [9] [10] In our TRAP model, high-grade prostatic intraepithelial neoplasia (PINs) are found from 4 weeks of age, and prostate adenocarcinomas in the ventral, dorsolateral and anterior lobes are observed at 100% incidences before 15 weeks of age. Prostate adenocarcinomas developing in TRAP are strictly androgen dependent in a pattern similar to that of human primary prostate cancer. TRAP lesions have many advantages, for example, their large size allows adequate materials to be obtained and development of prostate cancer occurs in a shorter experimental period and more efficiently compared with several other rat prostate carcinogenesis models. [11] [12] [13] [14] [15] [16] [17] [18] [19] These characteristics of TRAP may make it particularly suitable for evaluation of strategies for chemoprevention and treatment. The present study was conducted to assess whether finasteride and flutamide have the ability to suppress prostate carcinogenesis in our TRAP model.
Materials and methods

Animal and treatment
Male heterozygous TRAP rats established in our laboratory with a Sprague-Dawley genetic background were used in the present study. 8, 9 They were housed three/ cage on wood-chip bedding in an air-conditioned animal room at 23721C and 50710% humidity, with food (Oriental MF, Oriental Yeast Co., Tokyo, Japan) and tap water available ad libitum. Finasteride (Merck KGaA, Darmstadt, Germany) and flutamide (Nippon Kayaku Co. Ltd, Tokyo, Japan) were suspended in 0.5% methylcellulose 400 cP (Wako Pure Chemical Industries Ltd, Osaka, Japan) and administrated to 10-week-old TG rats five times a week via intragastric route at concentrations of 10 and 5 or 20 mg/kg, respectively. Animals were then killed at weeks 2, 5 and 7, and lesions in the prostate were histopathologically classified as described previously into PIN and adenocarcinoma categories. 8 The areas of lesions in each prostate sample were quantitatively measured with an Image Processor for Analytical Pathology (Sumika Technos Co., Osaka). Testosterone levels in serum were also analyzed by radioimmunoassay at a commercial laboratory (SRL, Tokyo).
The present experiment was performed under protocols approved by the Institutional Animal Care and Use Committee of Nagoya City University Graduate School of Medical Sciences.
Immunohistochemistry analysis
The avidin-biotin-peroxidase complex (ABC) method was used to determine the expression of the SV40 Tag and the AR in prostate epithelial cells. Prostate sections were treated with mouse anti-SV40 Tag (1:250, Pharmingen, San Diego, CA, USA), or rabbit anti-AR (1:200, Affinity Bioreagents, Golden, CO, USA) and then sequentially with secondary antibody and ABC (Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA, USA). The sites of peroxidase binding were demonstrated with diaminobenzidine as the substrate.
Statistical analysis
Statistical analysis of differences between means and incidences was carried out using analysis of variance and the Kruskal-Wallis test, respectively. When positive results were obtained, the Mann-Whitney U-test with Bonferroni correction was applied to evaluate the statistical significance between treatment groups.
Results
TRAP rats treated with finasteride or the high dose of flutamide for 5 and 7 weeks showed significantly (Po0.001) lower prostate weights relative to body weights as compared to controls (Table 1) . Macroscopically, prostates of TRAP in the non-treated group showed slight enlargement and irregular surfaces but no apparent nodule or mass formation. In contrast, antiandrogen treatment was associated with obvious prostate and seminal vesicle atrophy. Histopathological findings for prostatic lesions are summarized in Table 2 . Antiandrogen treatment for 2 weeks caused destruction of glandular structure with inflammatory cell infiltration ( Figure 1a) . After treatment for 7 weeks, atrophic glands were frequently observed with minimal nuclear atypia (Figures 1b and 2 ). PINs and/or adenocarcinomas were detected in all lobes. There were no statistically significant differences in the incidences of PINs or adenocarcinomas among the groups. However, the areas of lesions were significantly reduced in finasteride-and high dose of flutamide-treated groups in the ventral and lateral lobes, but not the dorsal lobe. The lesions also tended to be suppressed without significance by lowdose flutamide in all lobes (Table 3) .
Almost no expression of the SV40 Tag and only weak signals for AR were detected in involuted glands of rats treated with antiandrogens ( Figure 3 ). Serum testosterone levels were not influenced by finasteride treatment. On the other hand, the levels of testosterone were significantly (Po0.001) increased in the flutamide-treated groups in a dose-dependent manner at week 5. At week 7, however, levels had returned to normal level ( Figure 4 ). 20, 21 Among them, TG adenocarcinoma mouse prostate (TRAMP) model, harboring rat probasin promoter/SV40 Tag gene construct, is widely used. TRAMP mice demonstrated the development of well-differentiated adenocarcinomas in prostate by 10 weeks of age and of poorly differentiated metastatic, androgen-independent tumors by 28 weeks of age. 22, 23 In our TRAP rats, well-moderately differentiated adenocarcinomas similarly developed in prostate by 10-15 weeks of age. However, all adenocarcinomas in TRAP rats were completely androgen dependent and did not metastasize. 9 Hormonal factors play important roles in carcinogenesis as well as the homeostasis in the prostate gland. Because androgens promote prostate carcinogenesis, inhibition of androgenic functions is a fundamental approach to control prostate cancer. Our previous studies on the initiation and progression of prostate cancer using TRAP rats demonstrated that androgen depletion by orchiectomy at 5 or 20 weeks of age causes severe involution or regression, and inhibition of prostate carcinoma development, in clear contrast to the case with TRAMP mice that demonstrated the development of poorly differentiated prostate cancer with 80% incidence at 12 weeks after castration. 8, 23 Oral administration of finasteride for 2 months to methylnitrosourea/ testosterone propionate-inoculated male Wistar rats reduced the tumor incidence to 10%, as compared with the 64.3% of the control group. 24 Recently, the National Cancer Institute-sponsored Prostate Cancer Prevention Trial designed to investigate the efficacy of a variety of agents ranging from dietary supplements to laboratory manufactured drugs for the primary chemoprevention of prostate cancer demonstrated that finasteride can prevent prostate cancer. 25 The observed 25% reduction in the 7-year period prevalence of prostate cancer in men over age 55 years and few side effects 25 provides strong support for the importance of hormonal control for primary prostate cancer.
In the present study, there were massive or partial pathologic responses by flutamide or finasteride treatment as demonstrated by the reduction of prostatic neoplastic lesions in TRAP rats. However, these responses were not complete, that is, small or tiny foci of carcinoma were still remaining. Reflecting these findings, Abbreviations: Ca, carcinoma; PIN, prostatic intraepithelial neoplasia; TRAP, TG rat for adenocarcinoma of the prostate. there were no significant differences in the incidences of PIN or adenocarcinoma in the prostate of TRAP rats. In TRAMP mice, high-dose flutamide significantly decreased the incidence of only poorly differentiated tumors although well-differentiated tumors were observed more frequently, 6 suggesting that it is difficult to exert complete pathologic responses by flutamide alone against well-differentiated prostate tumors induced by Although there were no significant changes in serum testosterone concentration in the present study, relative prostate weights were obviously reduced by finasteride administration and prostate adenocarcinoma development was significantly suppressed. It is well known that treatment with flutamide causes a marked increase of serum testosterone associated with inhibition of the negative feedback response to testosterone by the hypothalamus. 27 The reason for return to a normal testosterone level after flutamide treatment for 7 weeks found here is unclear. It is plausible that continuous flutamide treatment acts at the level of the anterior pituitary gland by blocking the secretion of bioactive LH, thus depriving the testes of their physiologic stimulus and causing an arrest of androgen secretion. It has been shown that LH-releasing hormone (LHRH) agonists can transitionally stimulate serum testosterone release, and then reduce the level through blocking LH. 5 Treatment with the two antiandrogens here resulted in decreased expression of SV40 Tag via inhibition of AR function. The SV40 Tag acts as an oncoprotein through interaction with both retinoblastoma (Rb) 28 and p53 tumor-suppressor gene products. 29, 30 Loss of p53 and Rb genes has been implicated in the development of prostate cancer 31, 32 and in the TRAP model, SV40 Tag expression leads to abrogation of p53 and Rb functions, predisposing these cells to genetic instability. Although the TRAP model significantly differs from human prostate cancers regarding the status of p53 and Rb until late stages, it provides a very sensitive system to measure the consequence of hormone ablation in an in vivo model and assess the efficacy of potential androgen analogs because carcinogenesis in this model is primarily androgen driven. prostate carcinoma in situ at high incidence in F344 rats by a combination of 3, 
